Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY2275796
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
LY2275796 is a second-generation antisense oligonucleotide designed to inhibit the expression of eukaryotic translation initiation factor 4E (eIF-4E), a protein that regulates mRNA translation and is upregulated in various cancers. By blocking eIF-4E, LY2275796 reduces the synthesis of tumor angiogenic factors and growth/survival factors, thereby inhibiting tumor progression, angiogenesis, and metastasis. The drug was developed through a collaboration between Isis Pharmaceuticals (now Ionis Pharmaceuticals) and Eli Lilly. It has been investigated primarily for advanced solid tumors in clinical trials but has not demonstrated significant tumor response as monotherapy[1][2][3][4][5][7].
- Brand names
- ISIS EIF4ERx
- Other names
- eIF4E antisense oligonucleotideeIF-4E antisense oligonucleotideeIF 4E antisense oligonucleotide
02
Targets
Eukaryotic translation initiation factor 4E mRNA (eIF4E mRNA)
Beyond the preview
Go deeper on LY2275796.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY2275796.